Cargando…

BIMG-12. [18F]FLUCICLOVINE PET TO DISTINGUISH PSEUDOPROGRESSION FROM TUMOR PROGRESSION IN POST-TREATMENT GLIOBLASTOMA

PURPOSE: Differentiation of true tumor progression from pseudoprogression (PsP) is a major unmet need in patients with glioblastoma (GBM). [(18)F]Fluciclovine is a synthetic amino acid PET radiotracer that is FDA approved in the setting of biochemical recurrence in prostate cancer. The aim of this s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nabavizadeh, Ali, Doot, Robert, Young, Anthony, Nasrallah, MacLean, Ware, Jeffrey, Schubert, Erin, Henderson, Fraser, Pantel, Austin, Desai, Arati, Bagley, Stephen, O’Rourke, Donald, Brem, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992241/ http://dx.doi.org/10.1093/noajnl/vdab024.011

Ejemplares similares

(18)F-Fluciclovine PET to distinguish treatment-related effects from disease progression in recurrent glioblastoma: PET fusion with MRI guides neurosurgical sampling
por: Henderson, Fraser, et al.
Publicado: (2020)

Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas
por: de Godoy, Laiz Laura, et al.
Publicado: (2023)

BIMG-19. (18)F-FLUCICLOVINE PET/CT TO DISTINGUISH RADIATION NECROSIS FROM TUMOR PROGRESSION IN BRAIN METASTASES TREATED WITH STEREOTACTIC RADIOSURGERY: A PROSPECTIVE PILOT STUDY
por: Tom, Martin
Publicado: (2021)

Three‐dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma
por: Verma, Gaurav, et al.
Publicado: (2018)

2137 Percentage of viable tumor Versus radiation treatment effect in surgical specimens is not associated with outcomes in recurrent glioblastoma
por: Schwab, Robert D., et al.
Publicado: (2018)

F-18 Fluciclovine PET-CT Findings and Pseudoprogression on Immunotherapy
por: Poindexter, Bradley C, et al.
Publicado: (2022)

Arterial Spin Labeling and Dynamic Susceptibility Contrast-enhanced MR Imaging for evaluation of arteriovenous shunting and tumor hypoxia in glioblastoma
por: Nabavizadeh, S. Ali, et al.
Publicado: (2019)

BIMG-20. METABOLIC BIOMARKERS IN MICRODIALYSATE OF IDH-1 MUTANT TUMORS
por: Rajani, Karishma, et al.
Publicado: (2021)

BIMG-17. EFFECTS OF THE TUMOUR MICROENVIRONMENT ON PROTOPORPHYRIN IX ACCUMULATION IN GLIOBLASTOMA
por: Walker, Paul, et al.
Publicado: (2021)

BIMG-09. GLUTAMINE AND GLYCINE BY MR SPECTROSCOPY IDENTIFY AGGRESSIVE GLIOMAS
por: Choi, Changho, et al.
Publicado: (2021)

Imaging and histopathologic correlates of plasma cell-free DNA concentration and circulating tumor DNA in adult patients with newly diagnosed glioblastoma
por: Nabavizadeh, Seyed Ali, et al.
Publicado: (2020)

BIMG-18. ELEVATED CYSTATHIONINE IN MEDULLOBLASTOMA DEMONSTRATES TUMOR-SPECIFIC METHIONINE METABOLISM
por: Tikunov, Andrey, et al.
Publicado: (2021)

BIMG-10. IDH1 MUTATIONS INDUCE ORGANELLE DEFECTS VIA DYSREGULATED PHOSPHOLIPIDS
por: Yamasaki, Tomohiro, et al.
Publicado: (2021)

BIMG-06. RESPONSE ASSESSMENT OF BEVACIZUMAB THERAPY FOR GLIOBLASTOMA BY USING MULTIPLE PET TRACERS
por: Miyake, Keisuke, et al.
Publicado: (2021)

BIMG-11. PHARMACODYNAMIC EVALUATION OF IDH AND EGFR INHIBITION IN HUMAN GLIOMAS USING MOLECULAR MRI
por: Ellingson, Benjamin, et al.
Publicado: (2021)

BIMG-03. MOLECULAR IMAGING OF GLUCOSE METABOLISM FOR INTRAOPERATIVE FLUORESCENCE GUIDANCE DURING GLIOMA SURGERY
por: Belykh, Evgenii, et al.
Publicado: (2021)

BIMG-04. MAPPING HETEROGENEITY OF HIGH-GRADE GLIOMA METABOLISM USING HIGH RESOLUTION 7T MRSI
por: Hangel, Gilbert, et al.
Publicado: (2021)

BIMG-23. SINGLE-VOXEL VERSUS MULTI-SLICE MRSI IN PATIENTS WITH GLIOMA ON A KETOGENIC DIET INTERVENTION
por: Munjapara, Vasu, et al.
Publicado: (2021)

BIMG-07. PHARMACOLOGICAL ASCORBATE ENHANCES RADIATION AND TEMOZOLOMIDE EFFECTIVENESS IN GLIOBLASTOMA BY A MECHANISM MEDIATED BY REDOX ACTIVE IRON
por: Allen, Bryan, et al.
Publicado: (2021)

BIMG-21. DEUTERIUM METABOLIC IMAGING (DMI), A NEW, MRI-BASED TECHNIQUE FOR MAPPING BRAIN TUMOR METABOLISM IN VIVO
por: Corbin, Zachary, et al.
Publicado: (2021)

BIMG-22. DEEP LEARNING SUPER-RESOLUTION MR SPECTROSCOPIC IMAGING TO MAP TUMOR METABOLISM IN MUTANT IDH GLIOMA PATIENTS
por: Li, Xianqi, et al.
Publicado: (2021)

BIMG-14. IDENTIFICATION OF IDH MUTATION STATUS USING PROTON MR SPECTROSCOPY AND MASS SPECTROMETRY: A STUDY OF 178 GLIOMAS
por: Sacli-Bilmez, Banu, et al.
Publicado: (2021)

BIMG-13. A NOVEL RADIOPHARMACEUTICAL ([(18)F]DASA-23) TO MONITOR PYRUVATE KINASE M2 INDUCED GLYCOLYTIC REPROGRAMMING IN GLIOBLASTOMA
por: Beinat, Corinne, et al.
Publicado: (2021)

BIMG-02. IMAGING IMMORTALITY: TERT EXPRESSION ALTERS GLUCOSE METABOLISM IN LOW-GRADE GLIOMAS IN A MANNER THAT CAN BE LEVERAGED FOR NONINVASIVE METABOLIC IMAGING
por: Viswanath, Pavithra, et al.
Publicado: (2021)

BIMG-08. DEUTERIUM MAGNETIC RESONANCE SPECTROSCOPY USING (2)H-PYRUVATE ALLOWS NON-INVASIVE IN VIVO IMAGING OF TERT EXPRESSION IN BRAIN TUMORS
por: Batsios, Georgios, et al.
Publicado: (2021)

BIMG-15. LACTATE AND GLUTATHIONE LEVELS DETECTED WITH PROTON MR SPECTROSCOPY ARE ASSOCIATED WITH POOR SURVIVAL IN IDH WILD TYPE TERTP MUTANT DIFFUSE GLIOMAS
por: Sacli-Bilmez, Banu, et al.
Publicado: (2021)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma
por: Durgin, Joseph S., et al.
Publicado: (2021)

A dual-genotype oligoastrocytoma with histologic, molecular, radiological and time-course features
por: Nasrallah, Mac Lean P., et al.
Publicado: (2020)

BIMG-05. TO BE OR NOT TO BE GLYCOLYTIC: DEUTERATED GLUCOSE-BASED ASSESSMENT OF THE WARBURG EFFECT ALLOWS NON-INVASIVE IMAGING OF TUMOR BURDEN AND TREATMENT RESPONSE IN MUTANT IDH GLIOMAS IN VIVO
por: Taglang, Celine, et al.
Publicado: (2021)

Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imaging
por: Akbari, Hamed, et al.
Publicado: (2021)

BIMG-16. TRACKING TTFIELDS-INDUCED ALTERATIONS IN GLIOBLASTOMA METABOLISM WITH [18F]DASA-23, A NON-INVASIVE PROBE OF PYRUVATE KINASE M2 (PKM2)
por: Patel, Chirag, et al.
Publicado: (2021)

NEIM-02 DEVELOPMENT OF A DEEP LEARNING MODEL FOR DISCRIMINATING TRUE PROGRESSION FROM PSEUDOPROGRESSION IN GLIOBLASTOMA PATIENTS
por: Moassefi, Mana, et al.
Publicado: (2022)

Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma
por: Wang, Sumei, et al.
Publicado: (2018)

NEIM-03 A MULTICENTER PHASE 3 TRIAL IN PROGRESS: DIAGNOSTIC PERFORMANCE OF(18)F-FLUCICLOVINE PET FOR THE DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY (REVELATE)
por: Chao, Samuel, et al.
Publicado: (2022)

TRLS-02. Trial in Progress: A Multicenter Phase 3 Study to Establish the Diagnostic Performance of (18)F-Fluciclovine PET in Detecting Recurrent Brain Metastases after Radiation Therapy (REVELATE)
por: Teoh, Eugene, et al.
Publicado: (2021)

Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma
por: Bagley, Stephen J, et al.
Publicado: (2021)

Multi-institutional noninvasive in vivo characterization of IDH, 1p/19q, and EGFRvIII in glioma using neuro-Cancer Imaging Phenomics Toolkit (neuro-CaPTk)
por: Rathore, Saima, et al.
Publicado: (2021)

Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastoma
por: Fathi Kazerooni, Anahita, et al.
Publicado: (2022)

MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas
por: Hosseini, Seyyed Ali, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bkc6o8cp0l82d9k40agg141nqt